Ocugen Announced That The Data And Safety Monitoring Board For OCU410 ArMaDa Clinical Trial Recently Convened And Approved The Continuation Of The Second Phase Of The Phase 1/2 Study
Ocugen Announced That The Data And Safety Monitoring Board For OCU410 ArMaDa Clinical Trial Recently Convened And Approved The Continuation Of The Second Phase Of The Phase 1/2 Study
Ocugen宣佈，OCU410 ArMaDa臨床試驗的數據和安全監測委員會最近召開會議，批准繼續進行第一/第二階段研究的第二階段。
OCU410 (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).
OCU410 (AAV5-hRORA) 是一種新型修飾基因治療候選藥物，正在開發用於由於乾性年齡相關性黃斑變性 (dAMD) 導致的地理性萎縮 (GA)。